Capabilities by Region: Continental Europe
Greenhill has considerable advisory experience in Continental Europe. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout Continental Europe. Greenhill established its presence in Continental Europe in November 2000 with the opening of a Frankfurt office. Greenhill further expanded its presence with the opening of a Madrid office in 2017 and a Paris office in 2020.
For more information on Greenhill’s advisory practice in Continental Europe and our capabilities in the region, please contact President David Wyles in our London office, Managing Director Philip Meyer Horn in our Frankfurt office, Javier Gonzalez in our Madrid Office or Amélie Négrier-Oyarzabal in our Paris office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
Reliance Group
Advised Julius Bär Group Ltd., a leading Swiss private banking group, on its 95% acquisition of Reliance Group, one of the largest independent Brazilian wealth management firms with client assets of approximately BRL 17 billion (USD 5.3 billion)
CB&I
Advised McDermott International, Inc., a leading provider of integrated engineering, procurement, construction, installation and module fabrication services for upstream field developments worldwide, on its combination with CB&I, a leading provider of technology and infrastructure for the energy industry
36.5% stake in DNV GL Group AS
Advised Det Norske Veritas Holding AS (“DNV”) on its acquisition of the 36.5% stake in DNV GL Group AS it did not already own from Mayfair Vermögensverwaltungs SE, whereby DNV is becoming the sole shareholder and regaining full control of DNV GL
Grupo Sidecu
Advised the shareholders of Grupo Sidecu, the leading concessional sport center operator in Spain, on its sale of a controlling stake to Portobello Capital, a local private equity fund
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab